More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
Zach Pitluk, Ph.D.